F2G and Shionogi reported positive Phase 3 results for olorofim, their oral antifungal targeting invasive aspergillosis. The companies said the study met its primary non-inferiority objective against an established comparator, positioning olorofim for a potential regulatory path. The disclosure follows a broader resurgence in antifungal development as invasive mold infections continue to drive demand for new oral options. If confirmed in subsequent regulatory steps, olorofim could widen treatment options beyond existing IV-based therapies and shift some care toward outpatient-capable regimens. For biotech and pharma, the Phase 3 readout is likely to sharpen competitive dynamics in the difficult-to-treat aspergillosis market—where efficacy, safety, and practical administration are key differentiators.